Kidney cancer's developmental source revealed
Study reveals that kidney cancers may arise from cells that haven't fully developed, offering a new target for treatment
In the first experiment of its kind, scientists have revealed the precise identity of cancer cells of the most common childhood and adult kidney cancers. Researchers from the Wellcome Sanger Institute, the University of Cambridge, University of Newcastle and their collaborators showed that the cancer cells are versions of specific healthy cells from developing or adult kidneys.
Reported in the journal Science, this study could lead to the development of completely new methods of treating kidney cancers, which could persuade the cancerous cells to develop in specific ways into safer cells.
Kidney cancer is the seventh most common cancer in the UK with 12,500 new cases in 2015, mainly of adults with renal cell carcinomas. Treatments for this included surgery, chemotherapy and radiotherapy.
The most prevalent childhood kidney cancer is Wilms’ tumour, with about 80 children diagnosed each year in the UK. This mainly affects children under 5 years old, and although treatment for Wilms’ is usually successful, the chemotherapy can have serious long-term effects on the children.
In a huge study to understand these two most common types of kidney cancer, researchers looked at more than 72,000 individual kidney cells from healthy and cancerous tissue. They compared Wilms’ tumour and renal cell carcinoma cells with normal cells from developing, children’s, teen or adult kidneys.
Using a powerful technique called single-cell RNA sequencing, the researchers were able to find out the cancer cells’ precise identity. They discovered that children’s Wilms’ cancer cells have the same characteristics as a specific normal developing kidney cell, indicating that these kidney cells failed to develop properly in the womb.
“Our ground-breaking study identified the exact gene activity in each cell and revealed that Wilms’ tumour cells have the same characteristics of a normal developing kidney cell, which may have got ‘stuck’ during development. This could lead to an entirely new model for treating childhood cancer, by manipulating the development state of the cells instead of trying to kill them with chemotherapy.”
Dr Sam Behjati Leader of the study from the Wellcome Sanger Institute and Cambridge University’s Department of Paediatrics
“Using large-scale single cell RNA sequencing we could precisely define the characteristics of kidney tumour cells for the first time, and compare them with healthy reference kidney cells from different development stages and ages. This approach will help towards understanding not only kidney cancer, but many other diseases that have their origin during development.”
Professor Muzlifah Haniffa A corresponding author on the paper from Newcastle University*
The researchers also discovered that the adult renal carcinoma cells are a version of a specific rare subtype of healthy adult kidney cell, called PT1. They found that despite genetic differences, all the renal carcinoma cells studied had developed the same PT1 characteristics. The results could provide the basis of a new method for treating cancer by targeting this PT1 cell specifically.
“This study has importance beyond cancer. The inclusion of data from healthy developmental, child, adolescent, and adult kidney samples, has allowed us to generate the first human kidney cell atlas. This will make an important contribution towards the global Human Cell Atlas initiative that aims to map every cell in the human body and make this information available to researchers around the world.”
Dr Menna Clatworthy A corresponding author and principal investigator at the University of Cambridge Department of Medicine**
“Our work towards the Human Cell Atlas aims to make the data relevant to human disease and our understanding of human biology. This is a huge survey of epithelial cells of the human kidney throughout the human lifespan, which revolutionises our understanding of the kidney in health and cancer.”
Dr Sarah Teichmann A corresponding author on the paper from the Wellcome Sanger Institute***and co-chair of the Human Cell Atlas initiative
Matthew D Young, Thomas J Mitchell and Felipe A Vieira Braga, et al. (2018). Single cell transcriptomes from human kidneys reveal the cellular identity of renal tumours. Science. DOI: 10.1126/science.aat1699
Kidney cancer statistics from Cancer Research UK: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/kidney-cancer
*Muzlifah Haniffa is a Wellcome Senior Research Fellow in Clinical Sciences, Lister Institute Research Fellow, and Professor of Dermatology and Immunology at Newcastle University and NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals NHS Foundation Trust.
**Menna Clatworthy is principal investigator at the University of Cambridge Department of Medicine and an Honorary Consultant Nephrologist at Cambridge Universities NHS Foundation Trust.
*** Sarah Teichmann is Head of Cellular Genetics at the Wellcome Sanger Institute, and is affiliated with the University of Cambridge Dept of Physics. She is also the co-chair of the Human Cell Atlas Organising Committee.
This work was principally funded by the St Baldrick’s Foundation. Please see the paper for further funders.
As the largest private funder of childhood cancer research grants, the St. Baldrick’s Foundation is leading the charge to take childhood back from cancer. St. Baldrick’s funds some of the most brilliant childhood cancer research experts who are working to find cures and better treatments for all childhood cancers. Kids need treatments as unique as they are – and that starts with funding research just for them. Join us at StBaldricks.org to help support the best childhood cancer research, no matter where it takes place. https://www.stbaldricks.org/
Key facts about the University of Newcastle are available at https://www.ncl.ac.uk/press/about/keyfacts/
We are a centre for biomedical student teaching, research and clinical excellence for children and young adults
The Wellcome Sanger Institute is one of the world's leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease. To celebrate its 25th year in 2018, the Institute is sequencing 25 new genomes of species in the UK. Find out more at www.sanger.ac.uk or follow @sangerinstitute
Wellcome exists to improve health for everyone by helping great ideas to thrive. We’re a global charitable foundation, both politically and financially independent. We support scientists and researchers, take on big problems, fuel imaginations and spark debate. wellcome.org
30 Nov 2023
World’s largest genetic project opens the door to new era for treatments and cures: UK Biobank’s major milestone
The Wellcome Sanger Institute sequenced its share of 500,000 whole human genomes, contributing to the world’s largest single set ...
27 Nov 2023
Pocket-sized DNA sequencers track malaria drug resistance in near real-time
A team of scientists working in Ghana have pioneered on-site genomic surveillance to track changes in the malaria parasite, achieving sampling ...